Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramucirumab or Icrucumab with mFOLFOX-6 in 2nd Line Metastatic Colorectal Cancer
NCT01111604Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2010
- Primary completion
- Dec 2013
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of ramucirumab, icrucumab in metastatic colorectal cancer (mCRC), sponsored by Eli Lilly and Company. Started Aug 2010; status: completed.
02
Drugs
ramucirumabicrucumab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT01111604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01111604.